OVARIAN cancer is the seventh most commonly diagnosed malignancy among women worldwide, and the gynaecologic cancer with the worst prognosis and highest mortality. This is because of its resistance to common chemotherapeutic agents, vague and non-specific symptoms, and the lack of effective screening strategies for early detection. However, new research has suggested that poly(ADP-ribose) polymerase (PARP) inhibitors could potentially transform the treatment landscape of advanced ovarian cancer.
Latest articlesAll articles
Infographic: ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer
ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer. Bronchoscopy: for central lesions; can be paired with bronchial washing, brushing, and bronchial and transbronchial biopsy
Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer
Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC.
Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.
The Contradictory Phenomena: Development of a New Life and a Life-Threatening Illness: Colorectal Cancer in Pregnancy
Colorectal cancer (CRC) ranks as the third most common type of cancer in women. Patients aged 50 years and above constitute the highest percentage of patients diagnosed with the disease.